Elizabeth Ann Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses some of the top papers presented at the ASCO-SITC Symposium and how these presentations will affect clinical practice.
Roy S. Herbst, MD, PhD, of the Yale Cancer Center, discusses immunotherapy as a standard of care in lung cancer, critical biomarkers, and scientifically guided combination treatment, which will be the future of lung cancer immunotherapy.
Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discusses mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.
Stephen Gottschalk, MD, of Baylor College of Medicine and Texas Children’s Hospital, discusses combining CAR T cells with checkpoint blockade or targeted treatments to improve their antitumor activity in solid tumors.
Limo Chen, PhD, of The University of Texas MD Anderson Cancer Center, discusses co-inhibition of CD38 and PD-L1, which leads to improved antitumor immune response, reducing tumor growth and metastasis. (Abstract 79)
Holger N. Lode, MD, of the University of Greifswald, discusses in German the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor genotypes and Fc-receptor polymorphisms. (Abstract 111)
